Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v15-EN Version v5-EN
Language English English
Date Updated 2021-03-23 2020-07-08
Drug Identification Number 02401029 02401029
Brand name CEFAZOLIN FOR INJECTION, USP CEFAZOLIN FOR INJECTION, USP
Common or Proper name Cefazolin for Injection Cefazolin for Injection
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients CEFAZOLIN CEFAZOLIN
Strength(s) 100G 100G
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 100g SmartPak 100g SmartPak
ATC code J01DB J01DB
ATC description OTHER BETA-LACTAM ANTIBACTERIALS OTHER BETA-LACTAM ANTIBACTERIALS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2020-01-13 2020-01-13
Estimated end date 2021-03-22 2020-03-31
Actual end date 2021-03-22
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada Ltd. is pleased to advise that the following products have been removed from allocation as of today, Monday, March 22, 2021. The products will be available to all customers through all distribution channels without any volume restrictions. Allocation increased to 50% effective July 6, 2020
Health Canada comments